Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 3
1977 4
1978 2
1979 2
1980 4
1981 3
1982 9
1983 9
1984 9
1985 3
1986 3
1987 8
1988 3
1990 10
1991 7
1992 5
1993 14
1994 13
1995 2
1996 10
1997 6
1998 7
1999 11
2000 6
2001 7
2002 8
2003 14
2004 14
2005 10
2006 22
2007 22
2008 23
2009 18
2010 17
2011 7
2012 7
2013 2
2014 1
2015 1
2016 1
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

317 results
Results by year
Filters applied: . Clear all
Page 1
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Motzer RJ, et al. Among authors: bukowski rm. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044. N Engl J Med. 2007. PMID: 17215529 Free article. Clinical Trial.
Sorafenib in advanced clear-cell renal-cell carcinoma.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Escudier B, et al. Among authors: bukowski rm. N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655. N Engl J Med. 2007. PMID: 17215530 Free article. Clinical Trial.
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Motzer RJ, et al. Among authors: bukowski rm. J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487381 Free PMC article. Clinical Trial.
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Heng DY, et al. Among authors: bukowski rm. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826129
Pazopanib.
Bukowski RM, Yasothan U, Kirkpatrick P. Bukowski RM, et al. Nat Rev Drug Discov. 2010 Jan;9(1):17-8. doi: 10.1038/nrd3073. Nat Rev Drug Discov. 2010. PMID: 20043026
RANK ligand: effects of inhibition.
George S, Brenner A, Sarantopoulos J, Bukowski RM. George S, et al. Among authors: bukowski rm. Curr Oncol Rep. 2010 Mar;12(2):80-6. doi: 10.1007/s11912-010-0088-1. Curr Oncol Rep. 2010. PMID: 20425591 Review.
Temsirolimus: a safety and efficacy review.
Bukowski RM. Bukowski RM. Expert Opin Drug Saf. 2012 Sep;11(5):861-79. doi: 10.1517/14740338.2012.713344. Epub 2012 Aug 6. Expert Opin Drug Saf. 2012. PMID: 22861825 Review.
Novel drugs for renal cell carcinoma.
Vakkalanka BK, Bukowski RM. Vakkalanka BK, et al. Among authors: bukowski rm. Expert Opin Investig Drugs. 2008 Oct;17(10):1501-16. doi: 10.1517/13543784.17.10.1501. Expert Opin Investig Drugs. 2008. PMID: 18808310 Review.
SPLEEN/PATHOL.
Bukowski RM, Noguchi S, Hewlett JS, Deodhar S. Bukowski RM, et al. Am J Clin Pathol. 1976 Jan;65(1):30-9. Am J Clin Pathol. 1976. PMID: 1082240
317 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page